Seeking Alpha

ACADIA Pharmaceuticals (ACAD) announces Pimavanserin has met its primary and key secondary...

ACADIA Pharmaceuticals (ACAD) announces Pimavanserin has met its primary and key secondary endpoints in its Phase III Parkinson's Psychosis Trial. Shares are halted in premarket trading. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs